(HealthDay)—For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast cancer (SBC), according to a study published in the November issue of the Journal of the National Comprehensive Cancer Network.

Using the Surveillance, Epidemiology, and End Results database, Puyao C. Li, M.D., from Brigham and Women’s Hospital in Boston, and colleagues identified 3,407 patients who received breast-conserving therapy with or without RT for primary DCIS in 2000 through 2013 and subsequently developed a stage I to III invasive SBC.

The researchers found that even after controlling for cancer stage, prior RT was associated with higher rates of breast cancer-specific mortality (hazard ratio, 1.70; 95 percent confidence interval, 1.18 to 2.45; P = 0.005). The risk trended higher in patients with ipsilateral versus contralateral SBC (hazard ratio, 2.07 versus 1.26; P = 0.16). Patients with ipsilateral SBC were younger and more often lacked estrogen receptor expression compared with patients who developed contralateral SBC.

“These findings may have implications for treatment decision-making in DCIS and after development of SBC, and highlight the value of a careful discussion with patients before treatment,” the authors write.

Lumpectomy + radiation may cut breast cancer mortality in DCIS

More information: Abstract/Full Text

Copyright © 2019 HealthDay. All rights reserved.

Citation: Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer (2019, December 20) retrieved 22 December 2019 from https://medicalxpress.com/news/2019-12-radiotherapy-ductal-situ-carcinoma-ups.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Source: Radiotherapy for ductal in situ carcinoma ups mortality risk in invasive second breast cancer

Healthcare Startups & Investors

You have Successfully Subscribed!